Ποια είναι η τιμή για Thalia Therapeutics Plc (THAT)

Η τιμή για Thalia Therapeutics Plc (THAT) είναι $0.00884456

Ποια είναι η κεφαλαιοποίηση αγοράς για Thalia Therapeutics Plc (THAT)

Η κεφαλαιοποίηση αγοράς για Thalia Therapeutics Plc (THAT) είναι $73.61K

Thalia Therapeutics Plc (THAT) Τιμή και Κεφαλαιοποίηση Αγοράς

Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.

Η τιμή για THAT	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$653,893 $73.61K	NVDA	$5.442T	+7,393,161,044.48%
$536,270 $73.61K	AAPL	$4.463T	+6,063,274,714.73%
$501,765 $73.61K	GOOG	$4.176T	+5,673,142,815.77%
$442,104 $73.61K	MSFT	$3.680T	+4,998,601,747.23%
$344,725 $73.61K	AMZN	$2.869T	+3,897,597,459.79%

Η τιμή για THAT

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$653,893 $73.61K